Replies to post #790184 on NorthWest Biotherapeutics Inc (NWBO)

[sentiment_stocks]

What on earth?!

Biopsy's have much lower likelihood of death than a full resection.

Instead…

an overwhelming consistency of the evidence (including three class 2 studies) supports the superiority of GTR over STR and biopsy. We therefore suggest, based on three class II studies and many consistent class 3 studies, that GTR probably increases the likelihood of 1-year survival compared with STR by about 61% and increases the likelihood of 2-year survival by about 19%.
https://pmc.ncbi.nlm.nih.gov/articles/PMC6438173/

GTR: gross total resection
STR: subtotal resection
Biopsy: tissue sample from the tumor

I will note that GBM patients with biopsies only lived longer than the ECA patients. This data was presented at the May 10 NYAS event on one of the slides. I have a copy of that slide and can post it if anyone wants to see it when I have a chance (tomorrow) to search for it.

[Roman516]

GoLow, The OS data is the key and the P3 statistical guess is worthless.
The FDA knows that DCVax is successful, but you waste your time bashing NWBO per normal, IMO
Still waiting for your official proof from you as you claimed that the FDA officially rejected NWBO.